Latest updates for CUR TGTX TNXP

Jan 16, 2015 No Comments

Latest updates to the Company Pipeline Database from January 15, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated CUR 2.89 NSI-566 Amyotrophic lateral sclerosis (Lou Gehrig’s) Phase 2 Phase 2 data are due LATE 1Q or EARLY 2Q 2015 according to Jan 2015 presentation. 1/16/2015 TGTX […]

Read more

ETRM receives FDA Approval. CUR Phase 2 ALS data due 2Q. OPK NDA filing update + RGDO BCRX news

Jan 15, 2015 No Comments

Latest updates to the Company Pipeline Database from January 14, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated BCRX 11.41 BCX4161 – OPuS-2 Hereditary angioedema Phase 2b Phase 2b data due by end of 2015 1/15/2015 CUR 3.09 NSI-566 Amyotrophic lateral sclerosis (Lou Gehrig’s) Phase 2 Phase […]

Read more

Latest pipeline updates. 40 in total!

Jan 13, 2015 No Comments

Latest updates to the Company Pipeline Database from January 12 and 13, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ATRS 2.46 VIBEX QuickShot Testosterone deficiency Phase 3 Phase 3 initiated July 2014. Final patient dosed Nov 2015. Top-line pharmacokinetic data due 2Q 2015 1/14/2015 CPRX 2.87 […]

Read more

ARGS Phase 2 trial fail. PTLA Phase 3 Andexanet alfa meets endpoint + updates from ORPN RIGL SAGE TXNP

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 9, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ARGS 6.51 AGS-004 HIV Phase 2b Phase 2b trial did not meet endpoint – early Jan 2015 1/10/2015 ORPN 7.82 Cabaletta Oculopharyngeal Muscular Dystrophy Phase 2/3 Phase 2/3 HOPEMD […]

Read more

NBIX meets Phase 3 endpoint + updates for ALNY CNAT CYTR PLX GALE GWPH INFI IXPL KMDA LGND OTIC RGLS SGYP VSAR VSTM

Jan 09, 2015 No Comments

Latest updates to the Company Pipeline Database from January 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALNY 101.70 Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 trial initiated Nov 2013, continues to enrol patients as of Nov 2014. Expects […]

Read more

Pipeline updates for BIND CTIC DERM + ALKS to initiate pivotal ALKS 3831 trial

Jan 08, 2015 No Comments

Latest updates to the Company Pipeline Database from January 7, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Text Updated ALKS 66.75 ALKS 3831 Schizophrenia Phase 2 Phase 2 data released Jan 2015.Met primary endpoint, equivalence to olanzapine. Pivotal trial planned for 2015 1/8/2015 BIND 5.15 BIND-014 Cancer – […]

Read more

KBIO Phase 2 trial failure. CNAT data due this week + updates for ARIA CANF RARE TNXP TRVN AKBA BCLI CEMP CYTR MSTX RVNC RLYP GEVA

Jan 07, 2015 No Comments

Latest updates to the Company Pipeline Database from January 5 and 6, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ARIA 6.51 Iclusig (ponatinib) Cancer – refractory chronic-phase chronic myeloid leukemia (CP-CML) Phase 2 Phase 2 dose ranging trial to be initiated mid 2015 1/7/2015 CANF […]

Read more

Happy New Year + updates from AQXP CANF RPRX SYN TKMR XENT

Jan 01, 2015 No Comments

A very special Happy New Year to all readers of BioPharmCatalyst! Thank you for your support over the past year and I wish you a most prosperous 2015. Latest updates to the Company Pipeline Database from December 30 and 31,2014. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated […]

Read more

ATHX Multistem data due around end 1Q 2015. PTN initiates Phase 3 FSD trial.

Dec 29, 2014 No Comments

Latest updates to the Company Pipeline Database from December 26,2014. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ATHX 1.41 Multistem Ischemic stroke Phase 2 Initiated 3Q 2011. Enrolment completed late Dec 2014. Initial data due around the end of 1Q 2015 12/30/2014 PTN 0.79 Bremelanotide female […]

Read more